719 related articles for article (PubMed ID: 28384828)
1. Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age.
Baud O; Trousson C; Biran V; Leroy E; Mohamed D; Alberti C;
JAMA; 2017 Apr; 317(13):1329-1337. PubMed ID: 28384828
[TBL] [Abstract][Full Text] [Related]
2. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial.
Baud O; Maury L; Lebail F; Ramful D; El Moussawi F; Nicaise C; Zupan-Simunek V; Coursol A; Beuchée A; Bolot P; Andrini P; Mohamed D; Alberti C;
Lancet; 2016 Apr; 387(10030):1827-36. PubMed ID: 26916176
[TBL] [Abstract][Full Text] [Related]
3. Two-year neurodevelopmental outcomes of extremely preterm infants treated with early hydrocortisone: treatment effect according to gestational age at birth.
Baud O; Trousson C; Biran V; Leroy E; Mohamed D; Alberti C;
Arch Dis Child Fetal Neonatal Ed; 2019 Jan; 104(1):F30-F35. PubMed ID: 29321180
[TBL] [Abstract][Full Text] [Related]
4. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.
Doyle LW; Cheong JL; Ehrenkranz RA; Halliday HL
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD001146. PubMed ID: 29063585
[TBL] [Abstract][Full Text] [Related]
5. Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial.
Onland W; Cools F; Kroon A; Rademaker K; Merkus MP; Dijk PH; van Straaten HL; Te Pas AB; Mohns T; Bruneel E; van Heijst AF; Kramer BW; Debeer A; Zonnenberg I; Marechal Y; Blom H; Plaskie K; Offringa M; van Kaam AH;
JAMA; 2019 Jan; 321(4):354-363. PubMed ID: 30694322
[TBL] [Abstract][Full Text] [Related]
6. Early low-dose hydrocortisone: is the neurodevelopment affected?
Ofman G; Perez M; Farrow KN
J Perinatol; 2018 Jun; 38(6):636-638. PubMed ID: 29467523
[TBL] [Abstract][Full Text] [Related]
7. Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia.
Watterberg KL; Walsh MC; Li L; Chawla S; D'Angio CT; Goldberg RN; Hintz SR; Laughon MM; Yoder BA; Kennedy KA; McDavid GE; Backstrom-Lacy C; Das A; Crawford MM; Keszler M; Sokol GM; Poindexter BB; Ambalavanan N; Hibbs AM; Truog WE; Schmidt B; Wyckoff MH; Khan AM; Garg M; Chess PR; Reynolds AM; Moallem M; Bell EF; Meyer LR; Patel RM; Van Meurs KP; Cotten CM; McGowan EC; Hines AC; Merhar S; Peralta-Carcelen M; Wilson-Costello DE; Kilbride HW; DeMauro SB; Heyne RJ; Mosquera RA; Natarajan G; Purdy IB; Lowe JR; Maitre NL; Harmon HM; Hogden LA; Adams-Chapman I; Winter S; Malcolm WF; Higgins RD;
N Engl J Med; 2022 Mar; 386(12):1121-1131. PubMed ID: 35320643
[TBL] [Abstract][Full Text] [Related]
8. Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial.
Natalucci G; Latal B; Koller B; Rüegger C; Sick B; Held L; Bucher HU; Fauchère JC;
JAMA; 2016 May; 315(19):2079-85. PubMed ID: 27187300
[TBL] [Abstract][Full Text] [Related]
9. Neurodevelopmental outcome in extremely preterm infants at 2.5 years after active perinatal care in Sweden.
Serenius F; Källén K; Blennow M; Ewald U; Fellman V; Holmström G; Lindberg E; Lundqvist P; Maršál K; Norman M; Olhager E; Stigson L; Stjernqvist K; Vollmer B; Strömberg B;
JAMA; 2013 May; 309(17):1810-20. PubMed ID: 23632725
[TBL] [Abstract][Full Text] [Related]
10. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants.
Watterberg KL; Shaffer ML; Mishefske MJ; Leach CL; Mammel MC; Couser RJ; Abbasi S; Cole CH; Aucott SW; Thilo EH; Rozycki HJ; Lacy CB
Pediatrics; 2007 Jul; 120(1):40-8. PubMed ID: 17606560
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic hydrocortisone in extremely preterm infants and brain MRI abnormality.
Alison M; Tilea B; Toumazi A; Biran V; Mohamed D; Alberti C; Bourmaud A; Baud O;
Arch Dis Child Fetal Neonatal Ed; 2020 Sep; 105(5):520-525. PubMed ID: 31980445
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of Treatment Effects of Hydrocortisone by Risk of Bronchopulmonary Dysplasia or Death Among Extremely Preterm Infants in the National Institute of Child Health and Human Development Neonatal Research Network Trial: A Secondary Analysis of a Randomized Clinical Trial.
Gentle SJ; Rysavy MA; Li L; Laughon MM; Patel RM; Jensen EA; Hintz S; Ambalavanan N; Carlo WA; Watterberg K;
JAMA Netw Open; 2023 May; 6(5):e2315315. PubMed ID: 37256621
[TBL] [Abstract][Full Text] [Related]
13. Neurodevelopmental Outcomes of Extremely Preterm Infants Randomized to Stress Dose Hydrocortisone.
Parikh NA; Kennedy KA; Lasky RE; Tyson JE
PLoS One; 2015; 10(9):e0137051. PubMed ID: 26376074
[TBL] [Abstract][Full Text] [Related]
14. Effect of Maternal Docosahexaenoic Acid Supplementation on Bronchopulmonary Dysplasia-Free Survival in Breastfed Preterm Infants: A Randomized Clinical Trial.
Marc I; Piedboeuf B; Lacaze-Masmonteil T; Fraser W; Mâsse B; Mohamed I; Qureshi M; Afifi J; Lemyre B; Caouette G; Bartholomew J; Nuyt AM; Julien P; Synnes A; Lucas M; Perreault T; Strueby L; Cieslak Z; Yusuf K; Pelligra G; Massé E; Larsen B; de Cabo C; Ruth C; Khurshid F; Lavoie PM
JAMA; 2020 Jul; 324(2):157-167. PubMed ID: 32662862
[TBL] [Abstract][Full Text] [Related]
15. Hydrocortisone use in ventilated extremely preterm infants decreased bronchopulmonary dysplasia with no effects on neurodevelopment after two years.
Renault A; Patkaï J; Dassieu G; El Ayoubi M; Canouï-Poitrine F; Durrmeyer X
Acta Paediatr; 2016 Sep; 105(9):1047-55. PubMed ID: 27239054
[TBL] [Abstract][Full Text] [Related]
16. Placental Findings and Effect of Prophylactic Hydrocortisone in Extremely Preterm Infants.
Héneau A; Guimiot F; Mohamed D; Rideau Batista Novais A; Alberti C; Baud O;
Pediatrics; 2018 Feb; 141(2):. PubMed ID: 29348196
[TBL] [Abstract][Full Text] [Related]
17. Effect of Inhaled Nitric Oxide on Survival Without Bronchopulmonary Dysplasia in Preterm Infants: A Randomized Clinical Trial.
Hasan SU; Potenziano J; Konduri GG; Perez JA; Van Meurs KP; Walker MW; Yoder BA;
JAMA Pediatr; 2017 Nov; 171(11):1081-1089. PubMed ID: 28973344
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia.
Bassler D; Shinwell ES; Hallman M; Jarreau PH; Plavka R; Carnielli V; Meisner C; Engel C; Koch A; Kreutzer K; van den Anker JN; Schwab M; Halliday HL; Poets CF;
N Engl J Med; 2018 Jan; 378(2):148-157. PubMed ID: 29320647
[TBL] [Abstract][Full Text] [Related]
19. Mortality, In-Hospital Morbidity, Care Practices, and 2-Year Outcomes for Extremely Preterm Infants in the US, 2013-2018.
Bell EF; Hintz SR; Hansen NI; Bann CM; Wyckoff MH; DeMauro SB; Walsh MC; Vohr BR; Stoll BJ; Carlo WA; Van Meurs KP; Rysavy MA; Patel RM; Merhar SL; Sánchez PJ; Laptook AR; Hibbs AM; Cotten CM; D'Angio CT; Winter S; Fuller J; Das A;
JAMA; 2022 Jan; 327(3):248-263. PubMed ID: 35040888
[TBL] [Abstract][Full Text] [Related]
20. Association of Neurodevelopmental Outcomes and Neonatal Morbidities of Extremely Premature Infants With Differential Exposure to Antenatal Steroids.
Chawla S; Natarajan G; Shankaran S; Pappas A; Stoll BJ; Carlo WA; Saha S; Das A; Laptook AR; Higgins RD;
JAMA Pediatr; 2016 Dec; 170(12):1164-1172. PubMed ID: 27723868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
